Assessment of a potent ETA-selective receptor antagonist, ambrisentan, in IPF was terminated early due to worsening disease progression in the treatment (27%) versus control group (17%) (1). This evidence concerns the gene EDNRA and idiopathic pulmonary fibrosis.